Live from the NIH registry
Studies recruiting near Olathe right now
Top 25 of 1,038 recruiting studies, sorted by proximity — each links to its official registry page
One-Time DNA Study for Vasculitis
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis
N/A
Observational 1,000 participants sought
University of Kansas Medical Center — Kansas City, Kansas (19.0 mi)
· Sponsor: University of Pennsylvania
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia
Phase 1
Interventional 40 participants sought
Children's Mercy Hospital — Kansas City, Missouri (19.8 mi)
· Sponsor: Bleeding and Clotting Disorders Institute Peoria, Illinois
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Children's Mercy Hospitals and Clinics — Kansas City, Missouri (19.8 mi)
· Sponsor: National Cancer Institute (NCI)
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
Chronic Graft-versus-host Disease (cGVHD)
Phase 2
Interventional 120 participants sought
University of Kansas Cancer Center — Kansas City, Kansas (19.0 mi)
· Sponsor: H. Lee Moffitt Cancer Center and Research Institute
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer
Phase 3
Interventional 450 participants sought
HCA Midwest Health — Kansas City, Missouri (19.8 mi)
· Sponsor: Hoffmann-La Roche
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Ovarian Cancer, Fallopian Tube Cancer
Phase 2
Interventional 270 participants sought
334 — Kansas City, Missouri (19.8 mi)
· Sponsor: Corcept Therapeutics
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Phase 2
Interventional 164 participants sought
WISPer site in Kansas City, KS — Kansas City, Kansas (19.0 mi)
· Sponsor: Mediar Therapeutics
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
Sepsis, Acute Kidney Injury
Phase 2
Interventional 124 participants sought
Research Site — Kansas City, Kansas (19.0 mi)
· Sponsor: AstraZeneca
A Study of Buntanetap in Participants With PD
Parkinson's Disease (PD), Deep Brain Stimulation
Phase 2, Phase 3
Interventional 500 participants sought
University of Kansas Medical Center (KUMC) - School of Medicine - Parkinson's Disease and Movement D — Kansas City, Kansas (19.0 mi)
· Sponsor: Annovis Bio Inc.
Phase 2 Study to Assess the Safety and Efficacy of ANG003
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Phase 2
Interventional 113 participants sought
University of Kansas Medical Center — Kansas City, Kansas (19.0 mi)
· Sponsor: Anagram Therapeutics, Inc.
Regulating Together for Intellectual Disability and Autism: A Group Behavioral Therapy for for Emotion Dysregulation
Autism, Intellectual Disabilities With Other Behavioral Symptoms
N/A
Interventional 10 participants sought
Children's Mercy — Kansas City, Missouri (19.8 mi)
· Sponsor: Children's Mercy Hospital Kansas City
Nephrotic Syndrome Study Network
Minimal Change Disease (MCD), Membranous Nephropathy
N/A
Observational 1,200 participants sought
University of Kansas Medical Center — Kansas City, Kansas (19.0 mi)
· Sponsor: University of Michigan
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer, c-MET
Phase 3
Interventional 768 participants sought
St. Lukes Hosp. of Kansas City /ID# 259940 — Kansas City, Missouri (19.8 mi)
· Sponsor: AbbVie
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
Limb Girdle Muscular Dystrophy, Limb-Girdle Muscular Dystrophy Type 2
Phase 1, Phase 2
Interventional 10 participants sought
University of Kansas Medical Center — Kansas City, Kansas (19.0 mi)
· Sponsor: AskBio Inc
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
Rheumatoid Arthritis, Interstitial Lung Disease
N/A
Observational 450 participants sought
University of Kansas — Kansas City, Kansas (19.0 mi)
· Sponsor: University of Colorado, Denver
Inhaled Ciclesonide Study in Preterm Infants
Bronchopulmonary Dysplasia
Phase 1
Interventional 30 participants sought
Children's Mercy Kansas City — Kansas City, Missouri (19.8 mi)
· Sponsor: Venkatesh Sampath
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Solid Tumor, Adult, Metastatic Breast Cancer
Phase 1
Interventional 392 participants sought
St. Lukes Hospital of Kansas City — Kansas City, Missouri (19.8 mi)
· Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Prostate Cancer
Phase 3
Interventional 940 participants sought
University of Kansas Hospital — Kansas City, Kansas (19.0 mi)
· Sponsor: Novartis Pharmaceuticals
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer
Phase 3
Interventional 590 participants sought
The University of Kansas Cancer Center — Westwood, Kansas (15.4 mi)
· Sponsor: Revolution Medicines, Inc.
ELEVATE High-Risk PCI Pivotal Study
High-Risk Percutaneous Coronary Intervention (High-risk PCI)
N/A
Interventional 290 participants sought
St. Luke's Hospital of Kansas City — Kansas City, Missouri (19.8 mi)
· Sponsor: Magenta Medical Ltd.
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
Colo-rectal Cancer
Phase 2
Interventional 79 participants sought
University of Kansas Cancer Center — Kansas City, Kansas (19.0 mi)
· Sponsor: NSABP Foundation Inc
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
Parkinson Disease
N/A
Observational 4,500 participants sought
University of Kansas Medical Center — Kansas City, Kansas (19.0 mi)
· Sponsor: Michael J. Fox Foundation for Parkinson's Research
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Phase 3
Interventional 81 participants sought
Saint Luke's Hospital — Kansas City, Missouri (19.8 mi)
· Sponsor: Washington University School of Medicine
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Phase 3
Interventional 410 participants sought
University of Kansas Cancer Center — Westwood, Kansas (15.4 mi)
· Sponsor: AVEO Pharmaceuticals, Inc.
Group CBT in Parents of Children With Food Allergy
Parents
N/A
Interventional 10 participants sought
University Health Behavioral Health Canvas Building — Kansas City, Missouri (19.8 mi)
· Sponsor: University of Missouri, Kansas City